ExcerptAs biology shifts toward an engineering discipline, a Los Angeles biotech company, eXoZymes (Nasdaq: EXOZ), is betting that engineered enzyme systems can bridge the gap between digital molecule design and physical production.
Read the full Benzinga feature here